We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
- Authors
Farina, L.; Bruno, B.; Patriarca, F.; Spina, F.; Sorasio, R.; Morelli, M.; Fanin, R.; Boccadoro, M.; Corradini, P.
- Abstract
The hematopoietic cell transplantation specific comorbidity index (HCT-CI) has been developed to identify patients at high risk of mortality after an allograft. Reduced-intensity/non-myeloablative regimens have decreased the non-relapse mortality (NRM) in elderly and/or heavily pretreated patients. We performed a retrospective study to assess whether HCT-CI may predict clinical outcomes in a cohort of 203 patients with non-Hodgkin's (NHL; n=108), Hodgkin's lymphomas (HL; n=26), and multiple myeloma (MM; n=69), who were transplanted from a human leucocyte antigen (HLA)-matched sibling (n=121) or an unrelated donor (n=82) after a reduced-intensity regimen (n=154) or a low-dose total body irradiation-based non-myeloblative regimen (n=49). Cumulative incidence of NRM was 5, 16 and 20% at 1 year and 6, 24 and 27% at 2 years, for patients with an HCT-CI of 0, 1–2 and 3, respectively. By multivariate analysis, HCT-CI significantly predicted NRM (hazard ratio (HR)=1.6, P=0.03), overall survival (OS; HR=1.62, P<0.001) and progression-free survival (PFS; HR=1.43, P=0.002). Moreover, the Karnofsky performance status was also significantly associated with OS and NRM (HR=1.62, P<0.001 and HR=2.12, P=0.04, respectively). Conditioning type did not affect outcome after stratifying patients by HCT-CI. In the light of our study, all future prospective trials of the Gruppo Italiano Trapianti di Midollo (GITMO) will include the HCT-CI to stratify patients.Leukemia (2009) 23, 1131–1138; doi:10.1038/leu.2009.1; published online 5 February 2009
- Subjects
STEM cell transplantation; COMORBIDITY; LYMPHOMAS; TUMOR proteins; LYMPHOPROLIFERATIVE disorders
- Publication
Leukemia (08876924), 2009, Vol 23, Issue 6, p1131
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/leu.2009.1